Newspaper article Pittsburgh Post-Gazette (Pittsburgh, PA)

Epipen Sales Take Major Hit Skyrocketing Cost, More Competition Cited in Analysis

Newspaper article Pittsburgh Post-Gazette (Pittsburgh, PA)

Epipen Sales Take Major Hit Skyrocketing Cost, More Competition Cited in Analysis

Article excerpt

Concerns over the soaring cost of Mylan's EpiPen, plus increased competition, appear to have taken a toll on sales of the brand-name allergy shot.

Prescriptions for EpiPen alternatives surged to 28.9 percent of the market in February, up from 5.3 percent in December, according to a report by medical records and billing company Athenahealth in Watertown, Mass.

Put another way, the brand-name product's market share has fallen from around 95 percent to around 71 percent in February, the report said.

Athenahealth said it analyzed some 60,000 prescriptions for epinephrine auto-injectors written nationwide between January 2016 and February 2017. EpiPen held a 95.2 percent share in January 2016, Athenahealth said.

Mylan, which is run from executive offices in Cecil, did not respond to emails seeking comment. …

Search by... Author
Show... All Results Primary Sources Peer-reviewed

Oops!

An unknown error has occurred. Please click the button below to reload the page. If the problem persists, please try again in a little while.